Physician profile
Auguste Turnier
NPI 1225076326
$9,175.25
in general payments reported to CMS, 2019-2025
31 companies · $2,336 in 2025
The $2,336 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,117 · 2022: $1,346 · 2023: $1,467 · 2024: $2,909 · 2025: $2,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,712.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,839.71 | 2021-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,566.54 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $836.80 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $697.98 | 2023-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $660.64 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $604.56 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $555.58 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $528.38 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $273.59 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $243.62 | 2022-2025 | Linzess |
| Genzyme Corporation | $227.61 | 2022-2025 | |
| Lilly USA, LLC | $224.04 | 2024-2025 | Omvoh |
| Pfizer INC. | $106.36 | 2023-2024 | |
| Novo Nordisk INC | $99.70 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $96.49 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $85.37 | 2022 | |
| Madrigal Pharmaceuticals | $83.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Evoke Pharma, INC. | $59.89 | 2023-2024 | Gimoti |
| Merck Sharp & Dohme LLC | $59.42 | 2023-2024 | Dificid, Zinplava |
| Ipsen Biopharmaceuticals, INC | $52.53 | 2024-2025 | Bylvay, Iqirvo |
| Boston Scientific Corporation | $40.22 | 2024 | Watchman |
| Celltrion USA INC. | $34.23 | 2024-2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $31.78 | 2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $31.72 | 2021 | |
| Aimmune Therapeutics, INC. | $30.31 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $28.25 | 2021 | |
| Intercept Pharmaceuticals, INC. | $17.98 | 2025 | |
| Ge Healthcare | $16.82 | 2025 | |
| Fresenius Kabi USA, LLC | $16.68 | 2023 | Idacio |
| Organon LLC | $12.60 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Auguste Turnier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.